This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder

ADD / ADHD

centanafadine (EB-1020)

A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit Hyperactivity Disorder

There will be multiple cohorts dosed with open-label centanafadine.

This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 -
      12 years of age, inclusive) with a confirmed diagnosis of ADHD.

Trial at a glance

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

CT.gov ID:

Summary

Print or share trial information